secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000875045-25-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q1 revenue up 6% to $2.43B; Non-GAAP EPS $3.02 impacted by $165M Stoke upfront
--------------------------------------------------------------------------------

- GAAP diluted EPS $1.64, Non-GAAP $3.02; both down YoY due to ~($0.95) impact from Stoke upfront payment.
- LEQEMBI global in-market sales ~$96M; SKYCLARYS global revenue ~$124M; launch products more than doubled YoY.
- Updated FY2025 non-GAAP EPS guidance $14.50-$15.50; total revenue expected to decline mid-single-digit constant currency.
- Felzartamab Phase 3 study initiated in antibody-mediated rejection; BIIB080 (tau ASO) received FDA Fast Track designation.
- Zorevunersen collaboration with Stoke ($165M upfront) for Dravet syndrome; pivotal Phase 3 to start in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504525000014/0000875045-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504525000014/biib-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000875045-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer